Omnia Wellness (OMWS) S-1 15 Apr 22 IPO registration Financial data

Cover

Cover	9 Months Ended
	Dec. 31, 2021
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	OMNIA WELLNESS INC.
Entity Central Index Key	0001676852
Entity Tax Identification Number	98-1291924
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	999 18th Street
Entity Address, Address Line Two	Suite 3000
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80202
City Area Code	303
Local Phone Number	325-3738
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	999 18th Street
Entity Address, Address Line Two	Suite 3000
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80202
City Area Code	303
Local Phone Number	325-3738

Consolidated Balance Sheet

Consolidated Balance Sheet - USD ($)	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Current assets
Cash	$ 28,697	$ 28,761
Accounts Receivable	41,768	38,341
Due from related parties	305,600	163,200
Advances on Inventory	43,700	16,000	0
Total current assets	419,765	246,302
Non-current assets
Fixed assets, net	466,560	314,377
Intangible assets, net	1,450,900	1,600,975
Total non-current assets	1,917,460	1,915,352
Total Assets	2,337,225	2,161,654
Current liabilities:
Accounts payable and accrued expenses	330,011	103,205
Accrued interest	483,709	427,910	14,467
Accounts payable, related party	0	1,500	0
Deposit Liability	8,002	21,764
Payroll Liability	19,322
Warranty liability	25,667	25,667
Nonconvertible notes, related party		834,653	12,000
Nonconvertible notes, non relatd		1,745,000
Convertible notes, related party		29,970	6,546
Convertible notes, non related		1,107,143
Notes Payable	5,631,633	4,401,358
Total current liabilities	6,498,344	4,981,404
Total current liabilities		4,296,812	33,013
Non-current liabilities:
PPP Loan	0	588,891
Nonconvertible notes, related party		509,972
Nonconvertible notes, non related		174,620
Total non-current liabilities	0	588,891
Total non-current liabilities		1,273,483
Total liabilities	6,498,344	5,570,295
Total Liabilities		5,570,294	33,013
Stockholders’ deficit:
Preferred stock: Authorized - 150,000,000; Issued and outstanding 0 (March 31, 2020- 150,000,000 authorized and 0 issued and outstanding)
Common stock, par value $0.001; Authorized – 1,500,000,000; Issued and outstanding 224,227,107 (March 31, 2020- 1,500,000,000 authorized and 264,384,488 issued and outstanding)	14,900	14,900	55,058
Additional paid in capital benefit conversion feature on convertible notes	899,825	0
Additional paid-in capital	3,121,206	2,065,923	(10,224)
Accumulated deficit	(8,197,050)	(5,489,464)	(77,847)
Total stockholders’ deficit	(4,161,119)	(3,408,641)	(33,013)
Total stockholders’ deficit		(3,408,640)	(33,013)
Total Liabilities and Stockholders’ Deficit	$ 2,337,225	$ 2,161,654

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - $ / shares	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock authorized		10,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Preferred stock, shares authorized	150,000,000	150,000,000	150,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	1,500,000,000	1,500,000,000	1,500,000,000
Common stock, shares outstanding	229,905,146	224,227,107	264,384,488
Common stock, shares issued		224,227,107	264,384,488

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Revenue
Total Revenues	$ 56,833		$ 151,764		$ 218,874
Cost of goods sold, related party					120,253
Installation fees
Total cost of goods sold	2,904		17,914		120,253
Gross Profit	53,929		133,850		98,621
Operating expenses
Legal and professional fees	234,224		590,227		177,589
Warranty expense					13,399
Payroll expense	115,905		200,008		240,395
R&D Expense DryRx	205,000		937,000
Selling and marketing expense	14,495		45,415		52,804
Selling and marketing expense, related party					356,261
Consulting expense					25,985
Consulting expense, related party					244,186
License royalties					33,771
Impairment Expense
Depreciation and amortization	70,510		213,547		272,779
Bad Debt Expense	(2,200)		(2,200)
General and administrative	103,283	9,383	171,696	48,341	304,992	33,680
Total operating expenses	741,217	9,383	2,155,693	48,341	1,722,161	33,680
Income (loss) from operations	(687,288)	(9,383)	(2,021,843)	(48,341)
Other income (expense)
Interest income
Interest expense	105,403		379,465		(611,536)
Interest expense on beneficial conversion feature on convertible notes	128,250		899,825
Forgiveness of PPP Loan	(149,673)		(593,546)
Total other income (expense)	83,980		685,744		(611,536)
Net loss before income taxes	(771,268)	(9,383)	(2,707,587)	(48,341)
Income taxes
Net loss	$ (771,268)	$ (9,383)	$ (2,707,587)	$ (48,341)	$ (2,235,075)	$ (33,680)
Net loss per common share - Basic and Diluted	$ 0	$ 0	$ (0.01)	$ 0	$ (0.01)	$ 0
Weighted average number of common shares outstanding - Basic and Diluted	227,084,895	55,058,006	225,174,294	55,058,006	191,762,740	264,384,488
Sales Net [Member]
Revenue
Total Revenues					$ 218,124
Freight And Delivery [Member]
Revenue
Total Revenues					$ 750

Statements of Changes in Stockh

Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total	Preferred Stock [Member]
Beginning balance, shares at Mar. 31, 2019	264,384,488
Beginning balance, value at Mar. 31, 2019	$ 55,058	$ (24,923)	$ (44,167)	$ (14,032)
Forgiveness of Debt to Former Shareholder		14,699		14,699
Change in shares issued
Change in shares issued, shares
Conversion of Debt
Reverse Merger Consolidation Adjustment
Net loss			(33,680)	(33,680)
Balance at Mar. 31, 2020	$ 55,058	(10,224)	(77,847)	(33,013)
Ending balance, shares at Mar. 31, 2020	55,058,006
Ending balance, value at Mar. 31, 2020	$ 55,058	(10,224)	(77,847)	(33,013)
Ending balance, shares at Mar. 31, 2020	264,384,488
Change in shares issued
Change in shares issued, shares
Reverse Merger Consolidation Adjustment
Net loss			(275,957)	(275,957)
Balance at Jun. 30, 2020	$ 55,058	(10,224)	(353,804)	(308,970)
Ending balance, shares at Jun. 30, 2020	55,058,006
Balance, at Mar. 31, 2020	$ 55,058	(10,224)	(77,847)	(33,013)
Beginning balance, shares at Mar. 31, 2020	55,058,006
Beginning balance, value at Mar. 31, 2020	$ 55,058	(10,224)	(77,847)	(33,013)
Beginning balance, shares at Mar. 31, 2020	264,384,488
Change in shares issued	$ (40,158)			(40,158)
Change in shares issued, shares	(40,157,381)
Conversion of Debt		2,076,147		2,076,147
Reverse Merger Consolidation Adjustment			(3,176,541)	(3,176,541)
Net loss			(2,235,075)	(2,235,075)
Balance at Mar. 31, 2021	$ 14,900	2,065,923	(5,489,464)	(3,408,641)
Ending balance, shares at Mar. 31, 2021	14,900,629
Ending balance, value at Mar. 31, 2021	$ 14,900	2,065,923	(5,489,463)	(3,408,640)
Ending balance, shares at Mar. 31, 2021	224,227,107
Balance, at Jun. 30, 2020	$ 55,058	(10,224)	(353,804)	(308,970)
Beginning balance, shares at Jun. 30, 2020	55,058,006
Additional paid in capital		(1,054,216)	(1,054,216)	(1,054,216)
Reverse Merger Adjustment			(1,546,047)	(1,546,047)
Net loss			(850,922)	(850,922)
Balance at Sep. 30, 2020	$ 14,900	(1,064,440)	(3,451,185)	(4,500,725)
Ending balance, shares at Sep. 30, 2020	14,900,629
Balance, at Mar. 31, 2021	$ 14,900	2,065,923	(5,489,464)	(3,408,641)
Beginning balance, shares at Mar. 31, 2021	14,900,629
Stock Split, shares	209,326,478
Additional paid in capital		430,123		430,123
Net loss			(390,032)	(390,032)
Balance at Jun. 30, 2021	$ 14,900	2,496,046	(5,879,496)	(3,368,550)
Ending balance, shares at Jun. 30, 2021	224,227,107
Balance, at Mar. 31, 2021	$ 14,900	2,065,923	(5,489,464)	(3,408,641)
Beginning balance, shares at Mar. 31, 2021	14,900,629
Beginning balance, value at Mar. 31, 2021	$ 14,900	2,065,923	(5,489,463)	(3,408,640)
Beginning balance, shares at Mar. 31, 2021	224,227,107
Net loss				(2,707,587)
Balance at Dec. 31, 2021	$ 14,900	4,021,031	(8,192,570)	(4,161,119)
Ending balance, shares at Dec. 31, 2021	229,905,146
Balance, at Jun. 30, 2021	$ 14,900	2,496,046	(5,879,496)	(3,368,550)
Beginning balance, shares at Jun. 30, 2021	224,227,107
Additional paid in capital		754,291		754,291
Net loss			(1,546,286)	(1,546,286)
Balance at Sep. 30, 2021	$ 14,900	3,250,337	(7,425,782)	(4,160,545)
Ending balance, shares at Sep. 30, 2021	224,227,107
Additional paid in capital		770,694		770,694
Common Stock issued, shares	5,678,039
Net loss			(771,268)	(771,268)
Balance at Dec. 31, 2021	$ 14,900	$ 4,021,031	$ (8,192,570)	$ (4,161,119)
Ending balance, shares at Dec. 31, 2021	229,905,146

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,707,587)	$ (48,341)	$ (2,235,075)	$ (33,680)
Depreciation and amortization expense			272,779	215
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	225,306	38,826	152,136	(791)
Depreciation and amortization	214,086
Advance payments on purchase of inventory, related party			(16,000)
Inventory	(27,700)
Interest receivable
Interest payable			413,443	11,467
Accounts receivables, net	(3,428)		(38,341)
Due from related parties	(142,400)		(163,200)
Deposit Liability	(13,762)
PPP loan	(588,891)
Payroll Liability	19,322
Accrued interest	55,798
Interest expense on beneficial conversion feature on convertible notes	128,250
Net Cash Used In Operating Activities	(2,841,005)	(9,515)	(1,614,258)	(22,789)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(216,194)		(387,131)
Intangible assets, net
Payments on license agreement, related party			(1,801,000)
Net Cash Used In Investing Activities	(216,194)		(2,188,131)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from loan payable	1,230,275	9,515
Loans payable			3,603,654	12,000
Loans from shareholders			1,368,049	9,736
Change in shareholders’ equity, net			(1,100,394)
Change in common stock			(40,158)
Cash received from common stock	1,826,859
Net Cash Provided By Financing Activities	3,057,135	9,515	3,831,151	21,736
Net increase (decrease) in cash	(64)		28,761	(1,053)
Cash - Beginning of Year	28,761			1,053
Cash - End of Year	$ 28,697		$ 28,761

Nature of Operations

Nature of Operations	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Note 1 Nature of Operations Omnia Wellness Inc. (the “Company”) was incorporated as a Nevada corporation on March 2, 2016 Nevada On June 25, 2019, Maksim Charniak, the Company’s then sole executive officer and director and the owner of 3,000,000 95.6 On March 5, 2020, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to, among other things, (i) increase the Company’s authorized shares of common stock from 75,000,000 100,000,000 10,000,000 12.6374:1 On April 17, 2020, the Company entered into a Share Exchange and Reorganization Agreement (the “Exchange Agreement”) with Omnia Wellness Corporation (formerly known as Bed Therapies Inc.), a Texas corporation (“Omnia Corp.”), and the beneficial stockholders of Omnia Corp. to acquire 100 0.001 Accordingly, the Company acquired 100% of Omnia Corp. in exchange for the issuance of 10,000,000 (not adjusted to reflect the Company’s 15:1 forward stock split on April 6, 2021) shares of the Company’s common stock and Omnia Corp. became the Company’s wholly owned subsidiary. As of the closing of the Acquisition (the “Closing”), Mr. Samad, resigned as an officer and director of the Company and agreed to cancel 52,656,888 1,269,665 539,000 As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with RZI Consulting LLC (the “Assignment Agreement”), pursuant to which RZI Consulting LLC assumed substantially all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, the Company had no assets or liabilities (other than relating to general and administrative expenses). Following the Acquisition, the Company, through its wholly owned subsidiary Omnia Corp., now develops and markets products for wellness and physical therapy markets, using patented dry-hydro therapy equipment that the Company plans to offer and sell in medical and fitness markets. On April 6, 2021, the Company filed a Certificate of Change with the Secretary of State of the State of Nevada to (i) increase the Company’s authorized shares of common stock from 100,000,000 1,500,000,000 10,000,000 150,000,000 The Company’s principal executive office is located at 999 18 th In March 2020 the World Health Organization declared COVID-19 a pandemic. The Company is still assessing the impact COVID-19 may have on its business, but there can be no assurance that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.	Note 1 Nature of Operations Omnia Wellness Inc. ( the “Company”) was incorporated as a Nevada corporation on March 2, 2016 Nevada On June 25, 2019, Maksim Charniak, the Company’s then sole executive officer and director and the owner of 3,000,000 95.6 On March 5, 2020, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to, among other things, (i) increase the Company’s authorized shares of common stock from 75,000,000 100,000,000 10,000,000 12.6374:1 On April 17, 2020, the Company entered into a Share Exchange and Reorganization Agreement (the “Exchange Agreement”) with Omnia Wellness Corporation (formerly known as Bed Therapies Inc.), a Texas corporation (“Omnia Corp.”), and the beneficial stockholders of Omnia Corp. to acquire 100 0.001 Accordingly, the Company acquired 100% of Omnia Corp. in exchange for the issuance of 10,000,000 (not adjusted to reflect the Company’s 15:1 forward stock split on April 6, 2021) shares of the Company’s common stock and Omnia Corp. became the Company’s wholly-owned subsidiary. As of the closing of the Acquisition (the “Closing”), Mr. Samad, resigned as an officer and director of the Company and agreed to cancel 52,656,888 1,269,665 539,000 As of immediately prior to the closing of the Acquisition, the Company entered into an Assignment and Assumption Agreement with RZI Consulting LLC (the “Assignment Agreement”), pursuant to which RZI Consulting LLC assumed substantially all of the Company’s remaining assets and liabilities through the closing of the Acquisition. Accordingly, as of the closing of the Acquisition, the Company had no assets or liabilities (other than relating to general and administrative expenses). Following the Acquisition, the Company, through its wholly-owned subsidiary Omnia Corp., now develops and markets products for wellness and physical therapy markets, using patented dry-hydro therapy equipment that the Company plans to offer and sell in medical and fitness markets. On April 6, 2021, the Company filed a Certificate of Change with the Secretary of State of the State of Nevada to (i) increase the Company’s authorized shares of common stock from 100,000,000 1,500,000,000 10,000,000 150,000,000 The Company’s principal executive office is located at 999 18 th In March 2020 the World Health Organization declared COVID-19 a pandemic. The Company is still assessing the impact COVID-19 may have on its business, but there can be no assurance that this analysis will enable the Company to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 Summary of Significant Accounting Policies The principal accounting policies applied in the preparation of these financial statements are set out below. Basis of Presentation Principles of Consolidation - The consolidated financial statements include accounts of the Company’s wholly-owned subsidiary Omnia Wellness Corp., and Omnia Wellness Corp.’s wholly-owned subsidiary SolaJet™ Financing Company, LLC. All significant intercompany balances and transactions have been eliminated in consolidation. Accounting Estimates Risks and Uncertainties Loss Per Common Share - Basic net loss per common share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for each period presented. Diluted net loss per common share is computed by giving effect to all potential shares of common stock, including stock options and warrants, to the extent dilutive. As of December 31, 2021, and 2020, there were 229,905,146 and 55,058,006 , respectively, of common stock equivalents. Cash Related Party Transactions Advance Payments on Purchases of Inventory, related party 43,700 0 Fixed Assets - Fixed assets are carried at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives. The fixed assets include equipment placed in use at certain locations The accumulated depreciation was calculated to be $189,715 and $ 0 as of December 31, 2021, and 2020, respectively. Patent Cost 10 550,100 0 License Payable, related party Warranty Liability Beneficial Conversion Features Derivatives Revenue The Company derives its revenues primarily from the usage fees and sales of hydrotherapy massage beds and installation services. Revenues from sales are recognized when the products are sold and delivered to its customers and the usage fees are earned based on subscription or actual usage. Sales Taxes and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Shipping and handling fees charged to customers are reported within revenue. Income Taxes The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de- recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carrybacks and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary. Fair Value of Financial Instruments Fair Value Measurements and Disclosures ● Level 1: Quoted prices for identical assets and liabilities in active markets; ● Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ● Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, accounts payable, warrant liability and notes payable approximated fair value as of December 31, 2021, and 2020 due to the relatively short maturity of the respective instruments. Recently Issued Accounting Pronouncements - Leases (Topic 842) Leases (Topic 842): Targeted Improvements Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments	Note 2 Summary of Significant Accounting Policies The principal accounting policies applied in the preparation of these financial statements are set out below. Basis of Presentation Principles of Consolidation Accounting Estimates Risks and Uncertainties Loss Per Common Share 14,900,625 55,058,006 15 to 1 forward stock split 224,227,107 264,384,488 Cash Related Party Transactions Advance Payments on Purchases of Inventory, related party 16,000 0 Fixed Assets 108,746 0 Patent Cost 10 362,500 200,000 License Payable, related party Warranty Liability Beneficial Conversion Features Derivatives Revenue The Company derives its revenues primarily from the usage fees and sales of hydro therapy massage beds and installation services. Revenues from sales are recognized when the products are sold and delivered to its customers and the usage fees are earned based on subscription or actual usage. Sales Taxes and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Shipping and handling fees charged to customers are reported within revenue. Income Taxes The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary. Fair Value of Financial Instruments Fair Value Measurements and Disclosures ● Level 1: Quoted prices for identical assets and liabilities in active markets; ● Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ● Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, accounts payable, warrant liability and notes payable approximated fair value as of March 31, 2021 and 2020 due to the relatively short maturity of the respective instruments. Recently Issued Accounting Pronouncements – Leases (Topic 842) Leases (Topic 842): Targeted Improvements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments

Going Concern

Going Concern	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 Going Concern The Company adopted Accounting Standards Update No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”) The Company is commencing operations to generate sufficient revenue; however, the Company’s cash position may not be sufficient to support the Company’s daily operations. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of private offering. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.	Note 3 Going Concern The Company adopted Accounting Standards Update No. 2014-15, “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”) The Company is commencing operations to generate sufficient revenue; however, the Company’s cash position may not be sufficient to support the Company’s daily operations. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of private offering. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Parties

Related Parties	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Parties	Note 4 Related Parties The Company outsources its manufacturing pursuant to a Contract Services Agreement with DryRX, LLC dated as of January 1, 2020, which replaced and superseded the Contract Services Agreement with DryRX, LLC dated as of July 22, 2018, which expired in accordance with its terms. The Contract Services Agreement, among other things, provides that DryRX shall provide manufacturing and support services on behalf of the Company, and shall be responsible for the manufacturing oversight and production operations of the Company’s products. In return, the Company is obligated to pay to DryRX a fee equal to 10 % of net sales less cost-of-goods-sold and all expenses associated with the services. DryRX is owned and controlled by Steve Howe’s brother. The Company entered into a Consulting Agreement with Massagewave, Inc., owned and controlled by Steve Howe, to assist with business development and administrative activities. The agreement was entered into on May 1, 2018 and had required monthly payments of $ 15,000 April 30, 2020 68,262 0	Note 4 Related Parties The Company outsources its manufacturing pursuant to a Contract Services Agreement with DryRX, LLC dated as of January 1, 2020, which replaced and superseded the Contract Services Agreement with DryRX, LLC dated as of July 22, 2018 which expired in accordance with its terms. The Contract Services Agreement, among other things, provides that DryRX shall provide manufacturing and support services on behalf of the Company, and shall be responsible for the manufacturing oversight and production operations of the Company’s products. In return, the Company is obligated to pay to DryRX a fee equal to 10 The Company entered into a Consulting Agreement with Massagewave, Inc, owned and controlled by Steve Howe, to assist with business development and administrative activities. The agreement was entered into on May 1, 2018 and had required monthly payments of $ 15,000 April 30, 2020 25,985 0 1,500 0

Fixed Assets

Fixed Assets	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 5 Fixed Assets The carrying basis and accumulated depreciation of fixed assets at December 31, 2021 and 2020 is as follows: Schedule of Fixed Assets Useful Lives December 31, 2021 December 31, 2020 Inventory at 3 rd 5 $ 212,000 0 Equipment in use 5 $ 177,000 $ 0 Vehicles and Trailers 5 60,266 0 Patent Costs 10 2,001,000 0 Building improvements 40 207,009 0 Less depreciation and amortization 739,815 0 Total fixed assets, net $ 1,917,460 0 The Company recorded depreciation expense of $52,871 and $ 0 for the years ended December 31, 2021, and 2020, respectively.	Note 5 Fixed Assets The carrying basis and accumulated depreciation of fixed assets at March 31, 2021 and 2020 is as follows: Schedule of Fixed Assets Useful Lives March 31, 2021 March 31, 2020 Equipment in use 5 $ 99,000 $ - Equipment at 3 rd 5 212,000 - Building and Improvements 40 68,815 - Vehicles and trailers 5 60,266 - Less depreciation (125,704 ) Total fixed assets, net $ 314,377 - The Company recorded depreciation expense of $ 55,796 0

License Agreement, Related Part

License Agreement, Related Party	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
License Agreement Related Party
License Agreement, Related Party	Note 6 License Agreement, Related Party On April 30, 2019, the Company entered worldwide exclusive license with Drywave Technologies, Inc. (“Drywave”), a Company owned by Steve Howe. On the terms and conditions of the agreement, the Company received intellectual property rights to manufacture, use, and offer for sale all the products related to the patents and trademarks for dry hydrotherapy therapy technologies. The license fee to acquire the technology was $ 2,000,000 (a) $ 350,000 1,000 (b) $ 200,000 (c) $ 1,450,000 The Company made all the required payments as of March 31, 2021. After payment of the $2,000,000 License Fee, the Company pays to Drywave a royalty of 3% of Net Sales for the longer of the period in which there are valid patent claims or ten years. The Company is performing on this agreement The Company recorded the original license fee as an intangible asset as of April 30, 2019, and is amortizing the asset over the expected useful life of the asset of 10 years. The Company recorded amortization expense of $60,625 and $0 for the fiscal quarters ended December 31, 2021, and 2020, respectively.	Note 6 License Agreement, Related Party On April 30, 2019 the Company entered worldwide exclusive license with Drywave Technologies, Inc. (“Drywave”), a Company owned by Steve Howe. On the terms and conditions of the agreement, the Company received intellectual property rights to manufacture, use, and offer for sale all the products related to the patents and trademarks for dry hydrotherapy therapy technologies. The license fee to acquire the technology was $ 2,000,000 (a) $ 350,000 1,000 (b) $ 200,000 (c) $ 1,450,000 The Company made all the required payments as of March 31, 2021. After payment of the $ 2,000,000 The company recorded the original license fee as an intangible asset as of April 30, 2019 and is amortizing the asset over the expected useful life of the asset of 10 162,500 200,000

Notes Payable

Notes Payable	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 7 Notes Payable The following are the various notes payable of the Company: PPP Loan - 294,066 145,411 151,502.67 294,825 146,959 150,033 Nonconvertible notes, related party - 1,244,655 1,244,655 0 Schedule of Nonconvertible Notes Related Party Interest Rate Issuance Date Maturity December 31, 4.00 % 12/31/2018 12/31/2022 55,250 4.00 % 12/31/2018 12/31/2022 66,900 4.00 % 12/31/2018 12/31/2022 74,220 4.00 % 9/30/2019 9/29/2023 314,000 4.00 % 9/17/2019 9/16/2023 81,500 4.00 % 9/30/2019 9/29/2023 12,450 1.00 % 12/31/2020 12/30/2022 254,382 1.00 % 12/31/2020 12/30/2022 235,600 1.00 % 12/31/2020 12/30/2022 83,785 4.00 % 12/31/2020 12/31/2022 53,100 4.00 % 12/31/2020 12/31/2022 13,468 1,244,655 Nonconvertible notes, non-related- 2,565,527 2,374,219 191,308 Schedule of Nonconvertible Notes Non Related Interest Rate Default Rate Issuance Date Maturity December 31, 14.00 % 8/1/18 1/31/20 500,000 14.00 % Additional 2 % 10/30/19 10/29/20 229,500 14.00 % - 2/5/2020 2/5/2021 51,000 - % - % 2/28/2020 8/27/2020 322,219 20.00 % Additional 2 % 2/25/2020 8/24/2020 208,000 20.00 % Additional 2 % 2/28/2020 8/27/2020 102,000 14.00 % Additional 2 % 12/31/2019 12/31/2020 102,000 20.00 % Additional 2 % 4/24/2020 4/23/2021 20,000 30.00 % Additional 2 % 10/29/2020 2/28/2021 25,500 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 20.00 % - 2/5/2021 7/4/2021 68,000 18.20 % 25.00 % 9/18/2019 9/18/2023 23,347 18.20 % 25.00 % 10/9/2019 10/9/2023 37,037 18.20 % 24.00 % 3/10/2020 3/10/2024 90,654 15.00 % - 4/1/2021 3/31/2022 40,270 10.00 % - 4/1/2021 3/31/2022 100,000 12.00 % - 6/23/2021 6/22/2022 595,000 2,565,527 Convertible notes, related party 29,970 in unsecured notes payable to investors of the Company, bearing an annual interest rate of 4 % and a default interest rate of an additional 2 %. The notes are due December 30, 2023 unless sooner paid in full or converted in accordance with the terms of conversion, provided, however, that if a “Qualified IPO” does not occur on or before the maturity date, the maturity date shall be extended automatically for an additional one -year period and, during such period, the notes will bear interest at an annual rate of eight percent . Convertible notes, non related 1,349,443 10 one the notes will bear interest at an annual rate of ten percent (10%) Upon commencement by the Company of an underwritten initial public offering or the completed Exchange Agreement, of Borrower’s common stock, the note principal, together with all accrued and unpaid interest, will be converted into Shares as of the date of such commencement. After the share exchange was completed, the Company negotiated with the lenders to convert the loans for securities of the Company determined by dividing the outstanding balance of the note and accrued interest by $ 1.80 , subject to adjustment. Currently, the Company is in discussions with all Note holders to convert principal and interest into common shares of the Company. We expect a significant amount of the Notes to be converted in the next 60 days. The Company evaluates these notes at commencement for beneficial conversion features and derivatives and concluded there were none. Auctus Loan 650,000 4,333,333 0.15	Note 7 Notes Payable The following are the various notes payable of the Company: PPP Loan - 294,066 1.0% 144,065.87 Promissory Notes were due May 2022 and June 2025 and the balance of $ 444,825 Nonconvertible notes, related party - 1,334,007 824,035 509,972 Schedule of Nonconvertible Notes Related Party Interest Rate Issuance Date Maturity 3/31/2021 4.00 % 12/31/2018 12/31/2020 55,250 4.00 % 12/31/2018 12/31/2020 66,900 4.00 % 12/31/2018 12/31/2020 74,220 4.00 % 9/30/2019 9/29/2021 314,000 4.00 % 9/17/2019 9/16/2020 81,500 4.00 % 9/30/2019 9/29/2021 12,450 1.00 % 12/31/2020 12/30/2022 254,382 1.00 % 12/31/2020 12/30/2022 235,600 1.00 % 12/31/2020 12/30/2022 99,970 1.00 % 12/31/2020 12/30/2022 83,785 4.00 % 12/31/2020 12/31/2021 53,100 4.00 % 12/31/2020 12/31/2021 2,850 1,334,007 Nonconvertible notes, non related- 1,919,620 1,745,000 174,620 Schedule of Nonconvertible Notes Non Related Interest Rate Default Rate Issuance Date Maturity 3/31/2021 14.00 % 8/1/18 1/31/20 500,000 14.00 % Additional 2 % 10/30/19 10/29/20 229,500 14.00 % N/A 2/5/2020 2/5/2021 51,000 20.00 % Additional 2 % 2/28/2020 8/27/2020 204,000 20.00 % Additional 2 % 2/25/2020 8/24/2020 208,000 20.00 % Additional 2 % 2/28/2020 8/27/2020 102,000 20.00 % Additional 2 % 4/14/2020 10/13/2020 102,000 14.00 % Additional 2 % 12/31/2019 12/31/2020 102,000 20.00 % Additional 2 % 4/24/2020 4/23/2021 20,000 20.00 % Additional 2 % 8/21/2020 8/20/2021 10,000 30.00 % Additional 2 % 10/29/2020 2/28/2021 25,500 - 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 2/5/2021 140,000 14.20 % 25.00 % 9/18/2019 9/18/2023 26,560 14.20 % 25.00 % 10/9/2019 10/9/2023 49,840 14.20 % 25.00 % 3/10/2020 3/10/2024 98,220 1,919,620 Convertible notes, related party 29,970 4 2 December 30, 2021 Maturity Date one the notes will bear interest at an annual rate of eight percent (8%). Convertible notes, non related 1,147,610 4% December 2020 Maturity Date one the notes will bear interest at an annual rate of eight percent (8%). December 2021 Upon commencement by the Company of an underwritten initial public offering (a “ Qualified IPO Common Stock Conversion Date Conversion Price SEC The notes payable outstanding balance is as follows: Schedule of Notes Payable Outstanding Balance March 31, 2021 March 31, 2020 PPP Loan 558,891 - Nonconvertible notes, related party 834,653 12,000 Nonconvertible notes, non related 1,745,000 Convertible notes, related party 29,970 6,546 Convertible notes, non related 1,107,143 Less: Non-current portion of PPP Loan (588,891 ) - No-current portion of nonconvertible notes-related party (509,972 ) - Non-current portion of nonconvertible notes, non related (174,620 ) - Current notes payable 3,002,174 18,546

Shareholders_ Equity

Shareholders’ Equity	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Equity [Abstract]
Shareholders’ Equity	Note 8 Shareholders’ Equity Common Stock - 1,500,000,000 0.001 a. One non-cumulative vote for each share held of record on all matters submitted to a vote of the stockholders; b. To participate equally and to receive all such dividends as may be declared by the Board of Directors out of funds legally available; therefore, and c. To participate pro rata in any distribution of assets available for distribution upon liquidation. Stockholders have no pre-emptive rights to acquire additional shares of common stock or any other securities. Common shares are not subject to redemption and carry no subscription or conversion rights. Preferred Stock 10,000,000 150,000,000 No The Company has not declared or paid any dividends or returned any capital to common stock shareholders as of December 31, 2021, and 2020.	Note 8 Shareholders’ Equity (Deficit) Shareholders’ Equity Common Stock - 1,500,000 0.001 a. One non-cumulative vote for each share held of record on all matters submitted to a vote of the stockholders; b. To participate equally and to receive any and all such dividends as may be declared by the Board of Directors out of funds legally available therefore; and c. To participate pro rata in any distribution of assets available for distribution upon liquidation. Stockholders have no pre-emptive rights to acquire additional shares of common stock or any other securities. Common shares are not subject to redemption and carry no subscription or conversion rights. Preferred Stock 10,000,000 150,000,000 No The Company has not declared or paid any dividends or returned any capital to common stock shareholders as of March 31, 2021 and 2020.

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 Income Taxes Income Tax Expense For the fiscal year ended December 31, 2021, the reconciliation between the income tax benefit computed by applying the statutory U.S. federal income tax rate to the pre-tax loss before income taxes, and total income tax expense recognized in the financial statements is the change in the valuation allowance. For the fiscal year ended December 31, 2021, and 2020, the Company did not recognize any current income tax expense or benefit due to a full valuation allowance on its deferred income tax assets. NOL Carryforwards and Other Matters The Company files income tax returns in the U.S. federal jurisdiction and the state of Colorado. The Company’s federal and state tax years for the 2018 fiscal year and forward are subject to examination by taxing authorities. The Company did not have any unrecognized tax benefits as of December 31, 2021, and 2020. The Company’s policy is to account for any interest expense and penalties for unrecognized tax benefits as part of the income tax provision. The Company does not anticipate that unrecognized tax benefits will significantly increase or decrease within the next twelve months. Summary of Significant Deferred Income Tax Assets and Liabilities	Note 9 Income Taxes Income Tax Expense For the fiscal year ended March 31, 2021, the reconciliation between the income tax benefit computed by applying the statutory U.S. federal income tax rate to the pre-tax loss before income taxes, and total income tax expense recognized in the financial statements is the change in the valuation allowance. For the fiscal year ended March 31, 2021 and 2020, the Company did not recognize any current income tax expense or benefit due to a full valuation allowance on its deferred income tax assets. Deferred Income Tax Assets As of March 31 , Summary of Significant Deferred Income Tax Assets and Liabilities March 31, 2021 March 31, 2020 Deferred income tax assets: Net operating loss carryforwards 475,902 Other - (5,359 ) Total deferred income tax assets - 470,543 Valuation allowance for deferred income tax assets - (470,543 ) Net deferred income tax assets - - For the fiscal years ended March 31, 2021 and 2020, the valuation allowance increased primarily as a result of the increase in net operating losses. In assessing the realizability of deferred income tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. NOL Carryforwards and Other Matters The Company files income tax returns in the U.S. federal jurisdiction and the state of Colorado. The Company’s federal and state tax years for the 2018 fiscal year and forward are subject to examination by taxing authorities. The Company did not have any unrecognized tax benefits as of March 31, 2021 and 2020. The Company’s policy is to account for any interest expense and penalties for unrecognized tax benefits as part of the income tax provision. The Company does not anticipate that unrecognized tax benefits will significantly increase or decrease within the next twelve months.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 Commitments and Contingencies Off-Balance Sheet Arrangements - Leases - 200 The Company leases a warehouse facility of approximately 1,500 The Company leases approximately 4,500 square feet for the location of the new BodyStop™ located in the state of NY. The lease term is for 3 years and commenced on December 1, 2021 after substantial completion of the build out has been completed. The terms of the lease state the annual rent will increase by 3 % and a renewal option is available 60 days prior to the end of the lease for an additional 2 years with a 5 % annual increase in rent thereafter. Licenses 2 Legal Matters	Note 10 Commitments and Contingencies Off-Balance Sheet Arrangements – Leases – 200 The Company leases a warehouse facility of approximately 1,500 2 2 Legal Matters During the periods ended March 31, 2021 and 2020, there are no proceedings in which the Company or any of our directors, officers or affiliates, or any registered or beneficial shareholders, is an adverse party or has a material interest adverse to our interest. Subsequent Events - 100,000,000 1,500,000,000 10,000,000 150,000,000 1:15 forward stock split of the common stock. During the year ended March 31, 2021, the Company entered into PPP loans under the Paycheck Protection Program sponsored by the U.S. Small Business Administration (SBA) providing for aggregate proceeds of $ 588,891 294,066 294,825 Effective as of July 14, 2021, the principal amount of the Company’s Senior Secured Promissory Note (the “Note”) with Auctus Fund, LLC (the “Lender”) was increased by $ 25,000

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 11 Subsequent Events On February 17, 2022, Auctus and the Company executed a Waiver Letter which waived such defaults effective as of November 22, 2021. See “Note 7 Notes Payable-Auctus Loan” above.

Restatement

Restatement	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Restatement
Restatement	Note 12 Restatement The Company is in the process of restating its previously-filed Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2021 and subsequent quarterly filings to address certain SEC comments, including with respect to how the Company presented its April 2021 15-for-1	Note 11 Restatement The Company amended its Annual Report on Form 10-K for the fiscal year ended March 31, 2021 (the “Original Filing”), to restate its audited consolidated financial statements and related footnote disclosures to retroactively report an April 6, 2021, 15-1 forward stock split and delete the incorrect leases of inventory revenue disclosure statement for the period covered in the Original Filing. The Company currently does not hold any leases of inventory and has removed this disclosure from the footnotes of the financial statements in the Amendment No. 1 to the Original Filing, instead providing thatthe Company derives its revenues primarily from the usage fees and sales of hydro therapy massage beds and installation services. Revenues from sales are recognized when the products are sold and delivered to its customers and the usage fees are earned based on subscription or actual usage. Sales Taxes and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Shipping and handling fees charged to customers are reported within revenue. In addition, the weighted average earnings per share have been recalculated in the Consolidated Balance Sheets in the Amendment No. 1 to the Original Filing.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation - The consolidated financial statements include accounts of the Company’s wholly-owned subsidiary Omnia Wellness Corp., and Omnia Wellness Corp.’s wholly-owned subsidiary SolaJet™ Financing Company, LLC. All significant intercompany balances and transactions have been eliminated in consolidation.	Principles of Consolidation
Accounting Estimates	Accounting Estimates	Accounting Estimates
Risks and Uncertainties	Risks and Uncertainties	Risks and Uncertainties
Loss Per Common Share	Loss Per Common Share - Basic net loss per common share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding for each period presented. Diluted net loss per common share is computed by giving effect to all potential shares of common stock, including stock options and warrants, to the extent dilutive. As of December 31, 2021, and 2020, there were 229,905,146 and 55,058,006 , respectively, of common stock equivalents.	Loss Per Common Share 14,900,625 55,058,006 15 to 1 forward stock split 224,227,107 264,384,488
Cash	Cash	Cash
Related Party Transactions	Related Party Transactions	Related Party Transactions
Advance Payments on Purchases of Inventory, related party	Advance Payments on Purchases of Inventory, related party 43,700 0	Advance Payments on Purchases of Inventory, related party 16,000 0
Fixed Assets	Fixed Assets - Fixed assets are carried at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives. The fixed assets include equipment placed in use at certain locations The accumulated depreciation was calculated to be $189,715 and $ 0 as of December 31, 2021, and 2020, respectively.	Fixed Assets 108,746 0
Patent Cost	Patent Cost 10 550,100 0	Patent Cost 10 362,500 200,000
License Payable, related party	License Payable, related party	License Payable, related party
Warranty Liability	Warranty Liability	Warranty Liability
Beneficial Conversion Features	Beneficial Conversion Features	Beneficial Conversion Features
Derivatives	Derivatives	Derivatives
Revenue	Revenue The Company derives its revenues primarily from the usage fees and sales of hydrotherapy massage beds and installation services. Revenues from sales are recognized when the products are sold and delivered to its customers and the usage fees are earned based on subscription or actual usage. Sales Taxes and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Shipping and handling fees charged to customers are reported within revenue.	Revenue The Company derives its revenues primarily from the usage fees and sales of hydro therapy massage beds and installation services. Revenues from sales are recognized when the products are sold and delivered to its customers and the usage fees are earned based on subscription or actual usage. Sales Taxes and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Shipping and handling fees charged to customers are reported within revenue.
Income Taxes	Income Taxes The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de- recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carrybacks and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.	Income Taxes The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its balance sheets and provides valuation allowances as management deems necessary. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value Measurements and Disclosures ● Level 1: Quoted prices for identical assets and liabilities in active markets; ● Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ● Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, accounts payable, warrant liability and notes payable approximated fair value as of December 31, 2021, and 2020 due to the relatively short maturity of the respective instruments.	Fair Value of Financial Instruments Fair Value Measurements and Disclosures ● Level 1: Quoted prices for identical assets and liabilities in active markets; ● Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ● Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, accounts payable, warrant liability and notes payable approximated fair value as of March 31, 2021 and 2020 due to the relatively short maturity of the respective instruments.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements - Leases (Topic 842) Leases (Topic 842): Targeted Improvements Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments	Recently Issued Accounting Pronouncements – Leases (Topic 842) Leases (Topic 842): Targeted Improvements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	The carrying basis and accumulated depreciation of fixed assets at December 31, 2021 and 2020 is as follows: Schedule of Fixed Assets Useful Lives December 31, 2021 December 31, 2020 Inventory at 3 rd 5 $ 212,000 0 Equipment in use 5 $ 177,000 $ 0 Vehicles and Trailers 5 60,266 0 Patent Costs 10 2,001,000 0 Building improvements 40 207,009 0 Less depreciation and amortization 739,815 0 Total fixed assets, net $ 1,917,460 0	The carrying basis and accumulated depreciation of fixed assets at March 31, 2021 and 2020 is as follows: Schedule of Fixed Assets Useful Lives March 31, 2021 March 31, 2020 Equipment in use 5 $ 99,000 $ - Equipment at 3 rd 5 212,000 - Building and Improvements 40 68,815 - Vehicles and trailers 5 60,266 - Less depreciation (125,704 ) Total fixed assets, net $ 314,377 -

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Nonconvertible Notes Related Party	Schedule of Nonconvertible Notes Related Party Interest Rate Issuance Date Maturity December 31, 4.00 % 12/31/2018 12/31/2022 55,250 4.00 % 12/31/2018 12/31/2022 66,900 4.00 % 12/31/2018 12/31/2022 74,220 4.00 % 9/30/2019 9/29/2023 314,000 4.00 % 9/17/2019 9/16/2023 81,500 4.00 % 9/30/2019 9/29/2023 12,450 1.00 % 12/31/2020 12/30/2022 254,382 1.00 % 12/31/2020 12/30/2022 235,600 1.00 % 12/31/2020 12/30/2022 83,785 4.00 % 12/31/2020 12/31/2022 53,100 4.00 % 12/31/2020 12/31/2022 13,468 1,244,655	Schedule of Nonconvertible Notes Related Party Interest Rate Issuance Date Maturity 3/31/2021 4.00 % 12/31/2018 12/31/2020 55,250 4.00 % 12/31/2018 12/31/2020 66,900 4.00 % 12/31/2018 12/31/2020 74,220 4.00 % 9/30/2019 9/29/2021 314,000 4.00 % 9/17/2019 9/16/2020 81,500 4.00 % 9/30/2019 9/29/2021 12,450 1.00 % 12/31/2020 12/30/2022 254,382 1.00 % 12/31/2020 12/30/2022 235,600 1.00 % 12/31/2020 12/30/2022 99,970 1.00 % 12/31/2020 12/30/2022 83,785 4.00 % 12/31/2020 12/31/2021 53,100 4.00 % 12/31/2020 12/31/2021 2,850 1,334,007
Schedule of Nonconvertible Notes Non Related	Schedule of Nonconvertible Notes Non Related Interest Rate Default Rate Issuance Date Maturity December 31, 14.00 % 8/1/18 1/31/20 500,000 14.00 % Additional 2 % 10/30/19 10/29/20 229,500 14.00 % - 2/5/2020 2/5/2021 51,000 - % - % 2/28/2020 8/27/2020 322,219 20.00 % Additional 2 % 2/25/2020 8/24/2020 208,000 20.00 % Additional 2 % 2/28/2020 8/27/2020 102,000 14.00 % Additional 2 % 12/31/2019 12/31/2020 102,000 20.00 % Additional 2 % 4/24/2020 4/23/2021 20,000 30.00 % Additional 2 % 10/29/2020 2/28/2021 25,500 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 20.00 % - 2/5/2021 7/4/2021 68,000 18.20 % 25.00 % 9/18/2019 9/18/2023 23,347 18.20 % 25.00 % 10/9/2019 10/9/2023 37,037 18.20 % 24.00 % 3/10/2020 3/10/2024 90,654 15.00 % - 4/1/2021 3/31/2022 40,270 10.00 % - 4/1/2021 3/31/2022 100,000 12.00 % - 6/23/2021 6/22/2022 595,000 2,565,527	Schedule of Nonconvertible Notes Non Related Interest Rate Default Rate Issuance Date Maturity 3/31/2021 14.00 % 8/1/18 1/31/20 500,000 14.00 % Additional 2 % 10/30/19 10/29/20 229,500 14.00 % N/A 2/5/2020 2/5/2021 51,000 20.00 % Additional 2 % 2/28/2020 8/27/2020 204,000 20.00 % Additional 2 % 2/25/2020 8/24/2020 208,000 20.00 % Additional 2 % 2/28/2020 8/27/2020 102,000 20.00 % Additional 2 % 4/14/2020 10/13/2020 102,000 14.00 % Additional 2 % 12/31/2019 12/31/2020 102,000 20.00 % Additional 2 % 4/24/2020 4/23/2021 20,000 20.00 % Additional 2 % 8/21/2020 8/20/2021 10,000 30.00 % Additional 2 % 10/29/2020 2/28/2021 25,500 - 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 12.00 % Additional 2 % 10/30/2020 11/1/2021 25,500 2/5/2021 140,000 14.20 % 25.00 % 9/18/2019 9/18/2023 26,560 14.20 % 25.00 % 10/9/2019 10/9/2023 49,840 14.20 % 25.00 % 3/10/2020 3/10/2024 98,220 1,919,620
Schedule of Notes Payable Outstanding Balance		The notes payable outstanding balance is as follows: Schedule of Notes Payable Outstanding Balance March 31, 2021 March 31, 2020 PPP Loan 558,891 - Nonconvertible notes, related party 834,653 12,000 Nonconvertible notes, non related 1,745,000 Convertible notes, related party 29,970 6,546 Convertible notes, non related 1,107,143 Less: Non-current portion of PPP Loan (588,891 ) - No-current portion of nonconvertible notes-related party (509,972 ) - Non-current portion of nonconvertible notes, non related (174,620 ) - Current notes payable 3,002,174 18,546

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Summary of Significant Deferred Income Tax Assets and Liabilities	Summary of Significant Deferred Income Tax Assets and Liabilities	Summary of Significant Deferred Income Tax Assets and Liabilities March 31, 2021 March 31, 2020 Deferred income tax assets: Net operating loss carryforwards 475,902 Other - (5,359 ) Total deferred income tax assets - 470,543 Valuation allowance for deferred income tax assets - (470,543 ) Net deferred income tax assets - -

Nature of Operations (Details N

Nature of Operations (Details Narrative) - USD ($)	Apr. 06, 2021	Apr. 06, 2021	Jan. 05, 2021	Apr. 17, 2020	Mar. 05, 2020	Jun. 25, 2019	Mar. 02, 2016	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 04, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Entity incorporation, date of incorporation								Mar. 2, 2016	Mar. 2, 2016
Entity Incorporation, State or Country Code								NV
Equity method investment description								On June 25, 2019, Maksim Charniak, the Company’s then sole executive officer and director and the owner of 3,000,000 shares (pre- stock split) of the Company’s common stock, sold all his shares of common stock of the Company to Amer Samad, resulting in a change of control of the Company. As part of that transaction, Mr. Charniak resigned from all of his officer and director positions, and Mr. Samad was appointed as the Chief Executive Officer, President, Chief Financial Officer and Secretary of the Company, and was appointed to the Board of Directors of the Company. Mr. Samad also purchased 1,167,937 shares (pre-stock split) of the Company’s common stock in a series of private transactions, resulting in Mr. Samad owning 4,167,937 shares (pre-stock split) of the Company’s common stock, or approximately 95.6% of the issued and outstanding common stock of the Company	On June 25, 2019, Maksim Charniak, the Company’s then sole executive officer and director and the owner of 3,000,000 shares (pre-stock split) of the Company’s common stock, sold all of his shares of common stock of the Company to Amer Samad, resulting in a change of control of the Company. As part of that transaction, Mr. Charniak resigned from all of his officer and director positions, and Mr. Samad was appointed as the Chief Executive Officer, President, Chief Financial Officer and Secretary of the Company, and was appointed to the Board of Directors of the Company. Mr. Samad also purchased 1,167,937 shares (pre-stock split) of the Company’s common stock in a series of private transactions, resulting in Mr. Samad owning 4,167,937 shares (pre-stock split) of the Company’s common stock, or approximately 95.6% of the issued and outstanding common stock of the Company.
Common stock, shares authorized					100,000,000			1,500,000,000	1,500,000,000	1,500,000,000	75,000,000
Preferred stock authorized								150,000,000	150,000,000	150,000,000
Stockholders equity description					12.6374:1				15 to 1 forward stock split
Common stock, par value								$ 0.001	$ 0.001	$ 0.001
Entity incorporation, state or country code							NV
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares authorized	100,000,000	100,000,000
Preferred stock authorized	10,000,000	10,000,000
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares authorized	1,500,000,000	1,500,000,000
Preferred stock authorized	150,000,000	150,000,000
Exchange Agreement [Member] | Bed Therapies Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period shares stock splits			1,269,665
Ownership percentage				100.00%
Stockholders equity description		Accordingly, the Company acquired 100% of Omnia Corp. in exchange for the issuance of 10,000,000 (not adjusted to reflect the Company’s 15:1 forward stock split on April 6, 2021) shares of the Company’s common stock and Omnia Corp. became the Company’s wholly owned subsidiary. As of the closing of the Acquisition (the “Closing”), Mr. Samad, resigned as an officer and director of the Company and agreed to cancel 52,656,888		Accordingly, the Company acquired 100% of Omnia Corp. in exchange for the issuance of 10,000,000 (not adjusted to reflect the Company’s 15:1 forward stock split on April 6, 2021) shares of the Company’s common stock and Omnia Corp. became the Company’s wholly-owned subsidiary. As of the closing of the Acquisition (the “Closing”), Mr. Samad, resigned as an officer and director of the Company and agreed to cancel 52,656,888
Common stock, par value				$ 0.001
Debt principal amount				$ 539,000
Blank Check [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Preferred stock authorized					10,000,000
Mr. Amer Samad [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period shares stock splits						3,000,000
Ownership percentage						95.60%
Mr. Amer Samad [Member] | Exchange Agreement [Member] | Bed Therapies Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stockholders equity description	Company filed a Certificate of Change with the Secretary of State of the State of Nevada to (i) increase the Company’s authorized shares of common stock from 100,000,000 to 1,500,000,000, (ii) increase the Company’s authorized shares of “blank check” preferred stock from 10,000,000 to 150,000,000, and (iii) effect a 1:15 forward stock split of the common stock
Cancellation of stock split				52,656,888
Stockholders equity description	Company filed a Certificate of Change with the Secretary of State of the State of Nevada to (i) increase the Company’s authorized shares of common stock from 100,000,000 to 1,500,000,000, (ii) increase the Company’s authorized shares of “blank check” preferred stock from 10,000,000 to 150,000,000, and (iii) effect a 1:15 forward stock split of the common stock.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Mar. 05, 2020	Apr. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Short-term Debt [Line Items]
Number of anti-dilutive common stock			229,905,146	55,058,006	14,900,625	55,058,006
Advances on inventory			$ 43,700	$ 0	$ 16,000	$ 0
Accumulated depreciation			$ 189,715	0	$ 108,746	0
Intangible asset expected life		10 years	10 years		10 years
Accumulated amortization			$ 550,100	$ 0	$ 362,500	$ 200,000
Income tax, descripition			The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de- recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures		The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.
Stock split description	12.6374:1				15 to 1 forward stock split
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Number of anti-dilutive common stock					224,227,107	264,384,488

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Related Party Transaction [Line Items]
Payments of related party			$ 1,100,394
Consulting expense, related party	$ 68,262	$ 0	25,985	$ 0
Accounts payable, related party	$ 0		$ 1,500	$ 0
Contract Services Agreement [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Rate	10.00%		10.00%
Consulting Agreement [Member]
Related Party Transaction [Line Items]
Related party transaction, description	The Company entered into a Consulting Agreement with Massagewave, Inc., owned and controlled by Steve Howe, to assist with business development and administrative activities. The agreement was entered into on May 1, 2018 and had required monthly payments of $15,000 per month. The agreement expired on April 30, 2020, with renewal options. The agreement was renewed under the same terms and conditions and will expire April 30, 2023. The Company incurred consulting expense, related party of $68,262 and $0 as of December 31, 2021, and 2020, respectively. The due to and due from accounts are to various investors and related parties above for business related activities		The Company entered into a Consulting Agreement with Massagewave, Inc, owned and controlled by Steve Howe, to assist with business development and administrative activities. The agreement was entered into on May 1, 2018 and had required monthly payments of $15,000 per month. The agreement expired on April 30, 2020 with renewal options. The Company incurred consulting expense, related party of $25,985 and $-0- as of March 31, 2021 and 2020, respectively. The Company also has an accounts payable, related party balance of $1,500 and $-0- as of March 31, 2021 and 2020, respectively. The due to and due from accounts are to various investors and related parties above for business related activities.
Agreement expires date	Apr. 30, 2020		Apr. 30, 2020
Consulting Agreement [Member] | Massagewave Inc [Member]
Related Party Transaction [Line Items]
Payments of related party	$ 15,000		$ 15,000

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Property, Plant and Equipment [Line Items]
Less depreciation and amortization	$ 739,815	$ 125,704	$ 0
Total fixed assets, net	1,917,460	314,377
Total fixed assets, net			0
Less depreciation	$ (739,815)	$ (125,704)	0
Inventory [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Fixed assets, gross	$ 212,000		0
Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years	5 years
Fixed assets, gross	$ 177,000	$ 99,000	0
Vehicles and Trailers [Member]
Property, Plant and Equipment [Line Items]
Useful lives	5 years	5 years
Fixed assets, gross	$ 60,266	$ 60,266	0
Patent Costs [Member]
Property, Plant and Equipment [Line Items]
Useful lives	10 years
Fixed assets, gross	$ 2,001,000		0
Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful lives	40 years	40 years
Fixed assets, gross	$ 207,009	$ 68,815	$ 0
Equipment Third Party Locations [Member]
Property, Plant and Equipment [Line Items]
Useful lives		5 years
Fixed assets, gross		$ 212,000

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 52,871	$ 0	$ 55,796	$ 0

License Agreement, Related Pa_2

License Agreement, Related Party (Details Narrative) - USD ($)	Mar. 02, 2020	Oct. 30, 2019	Apr. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Aug. 30, 2019
Defined Benefit Plan Disclosure [Line Items]
Payment to acquire technology	$ 1,450,000	$ 200,000	$ 350,000			$ 1,801,000
Payment of escrow fee			$ 1,000
Intangible asset expected life			10 years	10 years		10 years
Amortization expense				$ 60,625	$ 0	$ 162,500	$ 200,000
Drywave Technologies Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Related party description						After payment of the $2,000,000 License Fee, the Company pays to Drywave a royalty of 3% of Net Sales for the longer of the period in which there are valid patent claims or ten years. The Company is performing on this agreement
Drywave Technologies Inc [Member] | License Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Payable on license fee acquired			$ 2,000,000					$ 2,000,000
Related party description						After payment of the $2,000,000 License Fee and not later than April 30, 2020, the Company will pay to Drywave a royalty of 3% of Net Sales beginning May 1, 2020 and continuing for the longer of the period in which there are valid patent claims or ten years. The Company is performing on this agreement.

Schedule of Nonconvertible Note

Schedule of Nonconvertible Notes Related Party (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Nonconvertible Notes Related Party One [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	4.00%
Issuance Date	Dec. 31, 2018	Dec. 31, 2018
Maturity	Dec. 31, 2022	Dec. 31, 2020
Unsecured Notes Payable	$ 55,250	$ 55,250
Nonconvertible Notes Related Party Two [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	4.00%
Issuance Date	Dec. 31, 2018	Dec. 31, 2018
Maturity	Dec. 31, 2022	Dec. 31, 2020
Unsecured Notes Payable	$ 66,900	$ 66,900
Nonconvertible Notes Related Party Three [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	4.00%
Issuance Date	Dec. 31, 2018	Dec. 31, 2018
Maturity	Dec. 31, 2022	Dec. 31, 2020
Unsecured Notes Payable	$ 74,220	$ 74,220
Nonconvertible Notes Related Party Four [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	4.00%
Issuance Date	Sep. 30, 2019	Sep. 30, 2019
Maturity	Sep. 29, 2023	Sep. 29, 2021
Unsecured Notes Payable	$ 314,000	$ 314,000
Nonconvertible Notes Related Party Five [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	4.00%
Issuance Date	Sep. 17, 2019	Sep. 17, 2019
Maturity	Sep. 16, 2023	Sep. 16, 2020
Unsecured Notes Payable	$ 81,500	$ 81,500
Nonconvertible Notes Related Party Six [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	4.00%
Issuance Date	Sep. 30, 2019	Sep. 30, 2019
Maturity	Sep. 29, 2023	Sep. 29, 2021
Unsecured Notes Payable	$ 12,450	$ 12,450
Nonconvertible Notes Related Party Seven [Member]
Short-term Debt [Line Items]
Interest Rate	1.00%	1.00%
Issuance Date	Dec. 31, 2020	Dec. 31, 2020
Maturity	Dec. 30, 2022	Dec. 30, 2022
Unsecured Notes Payable	$ 254,382	$ 254,382
Nonconvertible Notes Related Party Eight [Member]
Short-term Debt [Line Items]
Interest Rate	1.00%	1.00%
Issuance Date	Dec. 31, 2020	Dec. 31, 2020
Maturity	Dec. 30, 2022	Dec. 30, 2022
Unsecured Notes Payable	$ 235,600	$ 235,600
Nonconvertible Notes Related Party Nine [Member]
Short-term Debt [Line Items]
Interest Rate	1.00%	1.00%
Issuance Date	Dec. 31, 2020	Dec. 31, 2020
Maturity	Dec. 30, 2022	Dec. 30, 2022
Unsecured Notes Payable	$ 83,785	$ 99,970
Nonconvertible Notes Related Party Ten [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	1.00%
Issuance Date	Dec. 31, 2020	Dec. 31, 2020
Maturity	Dec. 31, 2022	Dec. 30, 2022
Unsecured Notes Payable	$ 53,100	$ 83,785
Nonconvertible Notes Related Party Eleven [Member]
Short-term Debt [Line Items]
Interest Rate	4.00%	4.00%
Issuance Date	Dec. 31, 2020	Dec. 31, 2020
Maturity	Dec. 31, 2022	Dec. 31, 2021
Unsecured Notes Payable	$ 13,468	$ 53,100
Nonconvertible Notes Related Party [Member]
Short-term Debt [Line Items]
Unsecured Notes Payable	$ 1,244,655	$ 1,334,007
Nonconvertible Notes Related Party Twelve [Member]
Short-term Debt [Line Items]
Interest Rate		4.00%
Issuance Date		Dec. 31, 2020
Maturity		Dec. 31, 2021
Unsecured Notes Payable		$ 2,850

Schedule of Nonconvertible No_2

Schedule of Nonconvertible Notes Non Related (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2021
Nonconvertible Notes Non Related One [Member]
Short-term Debt [Line Items]
Interest Rate	14.00%	14.00%
Issuance Date	Aug. 1, 2018	Aug. 1, 2018
Maturity	Jan. 31, 2020	Jan. 31, 2020
Unsecured Notes Payable	$ 500,000	$ 500,000
Nonconvertible Notes Non Related Two [Member]
Short-term Debt [Line Items]
Interest Rate	14.00%	14.00%
Issuance Date	Oct. 30, 2019	Oct. 30, 2019
Maturity	Oct. 29, 2020	Oct. 29, 2020
Unsecured Notes Payable	$ 229,500	$ 229,500
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Three [Member]
Short-term Debt [Line Items]
Interest Rate	14.00%	14.00%
Issuance Date	Feb. 5, 2020	Feb. 5, 2020
Maturity	Feb. 5, 2021	Feb. 5, 2021
Unsecured Notes Payable	$ 51,000	$ 51,000
Default Rate		N/A
Nonconvertible Notes Non Related Four [Member]
Short-term Debt [Line Items]
Interest Rate		20.00%
Issuance Date	Feb. 28, 2020	Feb. 28, 2020
Maturity	Aug. 27, 2020	Aug. 27, 2020
Unsecured Notes Payable	$ 322,219	$ 204,000
Default Rate		Additional 2
Nonconvertible Notes Non Related Five [Member]
Short-term Debt [Line Items]
Interest Rate	20.00%	20.00%
Issuance Date	Feb. 25, 2020	Feb. 25, 2020
Maturity	Aug. 24, 2020	Aug. 24, 2020
Unsecured Notes Payable	$ 208,000	$ 208,000
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Six [Member]
Short-term Debt [Line Items]
Interest Rate	20.00%	20.00%
Issuance Date	Feb. 28, 2020	Feb. 28, 2020
Maturity	Aug. 27, 2020	Aug. 27, 2020
Unsecured Notes Payable	$ 102,000	$ 102,000
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Seven [Member]
Short-term Debt [Line Items]
Interest Rate	14.00%	20.00%
Issuance Date	Dec. 31, 2019	Apr. 14, 2020
Maturity	Dec. 31, 2020	Oct. 13, 2020
Unsecured Notes Payable	$ 102,000	$ 102,000
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Eight [Member]
Short-term Debt [Line Items]
Interest Rate	20.00%	14.00%
Issuance Date	Apr. 24, 2020	Dec. 31, 2019
Maturity	Apr. 23, 2021	Dec. 31, 2020
Unsecured Notes Payable	$ 20,000	$ 102,000
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Nine [Member]
Short-term Debt [Line Items]
Interest Rate	30.00%	20.00%
Issuance Date	Oct. 29, 2020	Apr. 24, 2020
Maturity	Feb. 28, 2021	Apr. 23, 2021
Unsecured Notes Payable	$ 25,500	$ 20,000
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Ten [Member]
Short-term Debt [Line Items]
Interest Rate	12.00%	20.00%
Issuance Date	Oct. 30, 2020	Aug. 21, 2020
Maturity	Nov. 1, 2021	Aug. 20, 2021
Unsecured Notes Payable	$ 25,500	$ 10,000
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Eleven [Member]
Short-term Debt [Line Items]
Interest Rate	12.00%	30.00%
Issuance Date	Oct. 30, 2020	Oct. 29, 2020
Maturity	Nov. 1, 2021	Feb. 28, 2021
Unsecured Notes Payable	$ 25,500	$ 25,500
Debt instrument, default rate	2.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Twelve [Member]
Short-term Debt [Line Items]
Interest Rate	20.00%	12.00%
Issuance Date	Feb. 5, 2021	Oct. 30, 2020
Maturity	Jul. 4, 2021	Nov. 1, 2021
Unsecured Notes Payable	$ 68,000	$ 25,500
Default Rate		Additional 2
Nonconvertible Notes Non Related Thirteen [Member]
Short-term Debt [Line Items]
Interest Rate	18.20%	12.00%
Issuance Date	Sep. 18, 2019	Oct. 30, 2020
Maturity	Sep. 18, 2023	Nov. 1, 2021
Unsecured Notes Payable	$ 23,347	$ 25,500
Debt instrument, default rate	25.00%
Default Rate		Additional 2
Nonconvertible Notes Non Related Fourteen [Member]
Short-term Debt [Line Items]
Interest Rate	18.20%
Issuance Date	Oct. 9, 2019	Feb. 5, 2021
Maturity	Oct. 9, 2023
Unsecured Notes Payable	$ 37,037	$ 140,000
Debt instrument, default rate	25.00%
Nonconvertible Notes Non Related Fifteen [Member]
Short-term Debt [Line Items]
Interest Rate	18.20%	14.20%
Issuance Date	Mar. 10, 2020	Sep. 18, 2019
Maturity	Mar. 10, 2024	Sep. 18, 2023
Unsecured Notes Payable	$ 90,654	$ 26,560
Debt instrument, default rate	24.00%
Default Rate		25.00
Nonconvertible Notes Non Related Sixteen [Member]
Short-term Debt [Line Items]
Interest Rate	15.00%	14.20%
Issuance Date	Apr. 1, 2021	Oct. 9, 2019
Maturity	Mar. 31, 2022	Oct. 9, 2023
Unsecured Notes Payable	$ 40,270	$ 49,840
Default Rate		25.00
Nonconvertible Notes Non Related Seventeen [Member]
Short-term Debt [Line Items]
Interest Rate	10.00%	14.20%
Issuance Date	Apr. 1, 2021	Mar. 10, 2020
Maturity	Mar. 31, 2022	Mar. 10, 2024
Unsecured Notes Payable	$ 100,000	$ 98,220
Default Rate		25.00
Nonconvertible Notes Non Related Eighteen [Member]
Short-term Debt [Line Items]
Interest Rate	12.00%
Issuance Date	Jun. 23, 2021
Maturity	Jun. 22, 2022
Unsecured Notes Payable	$ 595,000
Nonconvertible Notes Non Related [Member]
Short-term Debt [Line Items]
Unsecured Notes Payable	$ 2,565,527	$ 1,919,620

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Oct. 29, 2021	Aug. 17, 2021	Jun. 24, 2021	May 12, 2021	May 04, 2021	Feb. 28, 2021	Dec. 31, 2021	Mar. 31, 2021
Securities Purchase Agreement [Member] | Auctus Fund LLC [Member]
Short-term Debt [Line Items]
Debt instrument principal amount			$ 650,000
Securities Purchase Agreement [Member] | Auctus Fund LLC [Member] | Warrant [Member]
Short-term Debt [Line Items]
Shares issued			4,333,333
Warrants exercise price			$ 0.15
Paycheck Protection Program Loan [Member]
Short-term Debt [Line Items]
Proceeds from loan								$ 294,066
Debt instrument, forgiveness				$ 151,502.67	$ 145,411
Paycheck Protection Program Including Interest	$ 150,033	$ 146,959
Paycheck Protection Program Loan [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Proceeds from loan								294,066
Debt instrument, forgiveness				$ 144,065.87				$ 444,825
Debt instrument, interest rate								1.00%
Debt instrument, description								Promissory Notes were due May 2022 and June 2025 and the balance of $444,825 may be forgiven subject to the terms of the Paycheck Protection Program.
CARES Act [Member]
Short-term Debt [Line Items]
Proceeds from loan						$ 294,825
Nonconvertible Notes Related Party [Member]
Short-term Debt [Line Items]
Unsecured notes payable							$ 1,244,655	$ 1,334,007
Nonconvertible Notes Related Party [Member] | Investor [Member]
Short-term Debt [Line Items]
Unsecured notes payable							1,244,655	1,334,007
Short term unsecured notes payable							1,244,655	824,035
Long term unsecured notes payable							0	509,972
Nonconvertible Notes Non Related [Member]
Short-term Debt [Line Items]
Unsecured notes payable							2,565,527	1,919,620
Nonconvertible Notes Non Related [Member] | Investor [Member]
Short-term Debt [Line Items]
Unsecured notes payable							2,565,527	1,919,620
Short term unsecured notes payable							2,374,219	1,745,000
Long term unsecured notes payable							191,308	174,620
Convertible Notes Related Party [Member] | Investor [Member]
Short-term Debt [Line Items]
Unsecured notes payable							$ 29,970	$ 29,970
Debt instrument, interest rate							4.00%	4.00%
Debt instrument, default interest rate							2.00%	2.00%
Debt instrument, maturity date							Dec. 30, 2023	Dec. 30, 2021
Debt instrument, description							one
Debt instrument, interest rate terms							the notes will bear interest at an annual rate of eight percent	the notes will bear interest at an annual rate of eight percent (8%).
Debt instrument term								1 year
Convertible Notes Non Related [Member]
Short-term Debt [Line Items]
Debt Instrument, Convertible, Conversion Price							$ 1.80
Convertible Notes Non Related [Member] | Investor [Member]
Short-term Debt [Line Items]
Unsecured notes payable							$ 1,349,443	$ 1,147,610
Debt instrument, interest rate							10.00%	4.00%
Debt instrument, maturity date								Dec. 31, 2020
Debt instrument, description							one
Debt instrument, interest rate terms							the notes will bear interest at an annual rate of ten percent (10%)	the notes will bear interest at an annual rate of eight percent (8%).
Debt instrument term								1 year
Convertible Notes Non Related [Member] | Investor [Member] | Extended Maturity [Member]
Short-term Debt [Line Items]
Debt instrument, maturity date								Dec. 31, 2021

Shareholders_ Equity (Details N

Shareholders’ Equity (Details Narrative) - $ / shares	Dec. 31, 2021	Apr. 06, 2021	Mar. 31, 2021	Mar. 31, 2020	Mar. 05, 2020	Mar. 04, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized	1,500,000,000		1,500,000,000	1,500,000,000	100,000,000	75,000,000
Common stock par value	$ 0.001		$ 0.001	$ 0.001
Preferred stock, shares authorized	150,000,000		150,000,000	150,000,000
Preferred stock, shares outstanding	0		0	0
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized			1,500,000
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized		100,000,000
Preferred stock, shares authorized		10,000,000
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized		1,500,000,000
Preferred stock, shares authorized		150,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Apr. 06, 2021shares	Dec. 31, 2021ft²shares	Mar. 31, 2021USD ($)ft²shares	Jul. 14, 2021USD ($)	Mar. 31, 2020shares	Mar. 05, 2020shares	Mar. 04, 2020shares
Loss Contingencies [Line Items]
Area of land | ft²		200	200
[custom:LeaseAssetUsefulLife]		3 years
[custom:AdditionalLeaseCostAssetUsefulLife]		2 years
Common stock, shares authorized		1,500,000,000	1,500,000,000		1,500,000,000	100,000,000	75,000,000
Preferred stock, shares authorized		150,000,000	150,000,000		150,000,000
Stock split	1:15 forward stock split of the common stock.
Ppp Loans [Member]
Loss Contingencies [Line Items]
Aggregate proceeds from loan | $			$ 588,891
First Ppp Loans [Member] | May Twelve Two Thousand Twenty One [Member]
Loss Contingencies [Line Items]
Debt forgiven | $			294,066
Second Ppp Loans [Member] | In Two Thousand Twenty One [Member]
Loss Contingencies [Line Items]
Debt forgiven | $			$ 294,825
Senior Secured Promissory Note [Member] | Auctus Fund LLC [Member]
Loss Contingencies [Line Items]
Debt, increase in principal amount | $				$ 25,000
Minimum [Member]
Loss Contingencies [Line Items]
Common stock, shares authorized	100,000,000
Preferred stock, shares authorized	10,000,000
Maximum [Member]
Loss Contingencies [Line Items]
Common stock, shares authorized	1,500,000,000
Preferred stock, shares authorized	150,000,000
Master Facility License Agreement [Member]
Loss Contingencies [Line Items]
Area of land | ft²			1,500
[custom:AdditionalLeasePercentage]		5.00%
Gross revenue percentage		2.00%	2.00%
Lease expiration period			2 years
Warehouse Facility [Member]
Loss Contingencies [Line Items]
Area of land | ft²		1,500
NewBody Stop [Member]
Loss Contingencies [Line Items]
Area of land | ft²		4,500
[custom:LeaseCostRatePercent]		3.00%

Schedule of Notes Payable Outst

Schedule of Notes Payable Outstanding Balance (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Short-term Debt [Line Items]
Current notes payable	$ 3,002,174	$ 18,546
P P P Loan [Member]
Short-term Debt [Line Items]
Notes payable	558,891
Non-current notes payable	(588,891)
Nonconvertible Notes Related Party [Member]
Short-term Debt [Line Items]
Notes payable	834,653	12,000
Non-current notes payable	(509,972)
Nonconvertible Notes Non Related [Member]
Short-term Debt [Line Items]
Notes payable	1,745,000
Non-current notes payable	(174,620)
Convertible Notes Related Party [Member]
Short-term Debt [Line Items]
Notes payable	29,970	$ 6,546
Convertible Notes Non Related [Member]
Short-term Debt [Line Items]
Notes payable	$ 1,107,143

Summary of Significant Deferred

Summary of Significant Deferred Income Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Restatement
Net operating loss carryforwards		$ 475,902
Other		(5,359)
Total deferred income tax assets		470,543
Valuation allowance for deferred income tax assets		(470,543)
Net deferred income tax assets

Restatement (Details Narrative)

Restatement (Details Narrative)	9 Months Ended
	Dec. 31, 2021
Restatement
Forward stock split description	15-for-1